Study | Dasatinib | Nilotinib 600 mg | Nilotinib 800 mg | Imatinib 400 mg | Imatinib 800 mg |
---|---|---|---|---|---|
Complete cytogenic response | |||||
6 months | Â | Â | Â | Â | Â |
DASISION | 73.0% | Â | Â | 59.2% | Â |
ENESTed | Â | 67.0% | 63.0% | 44.9% | Â |
Baccarani et al. | Â | Â | Â | 50.0% | 51.9% |
German CML Study IV | Â | Â | Â | 21.5% | 33.5% |
Cortes et al. 2010 | Â | Â | Â | 44.6% | 56.7% |
ISTAHIT | Â | Â | Â | 19.8% | 43.8% |
SPIRIT | Â | Â | Â | 50.0% | 69.0% |
12 months | Â | Â | Â | Â | Â |
DASISION study group | 83.4% | Â | Â | 71.5% | Â |
ENESTed study group | Â | 80.1% | 77.9% | 65.0% | Â |
Baccarani et al. (2009) | Â | Â | Â | 58.3% | 63.9% |
German CML Study IV | Â | Â | Â | 49.8% | 63.2% |
Cortes et al. 2010 | Â | Â | Â | 65.6% | 69.9% |
S0325 Intergroup Trial | 82.0% | Â | Â | 69.0% | Â |
SPIRIT | Â | Â | Â | 58.0% | 65.0% |
18 months | Â | Â | Â | Â | Â |
Dasatinib Study Group | 88.6% | Â | Â | Â | Â |
DASISION study group | 78.0% | Â | Â | 70.0% | Â |
ENESTed study group | Â | 85.0% | 82.0% | 74.0% | Â |
German CML Study IV | Â | Â | Â | 66.6% | 73.8% |
Major Molecular response | |||||
12 months | Â | Â | Â | Â | Â |
Bacarrani et al. (2009) | Â | Â | Â | 33.3% | 39.8% |
DASISION study group | 45.9% | Â | Â | 28.1% | Â |
ENESTed Study group | Â | 44.0% | 43.1% | 21.9% | Â |
German CML Study IV | Â | Â | Â | 30.8% | 54.8% |
Cortes et al. 2010 | Â | Â | Â | 40.1% | 46.4% |
SPIRIT | Â | Â | Â | 38.0% | 49.0% |
S0325 Intergroup Trial | 59.0% | Â | Â | 43.0% | Â |